Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.58 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.58 |
| ▸ | APOB | P04114 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | MTTP | P55157 | 5/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | PPARG | P37231 | 2/20 | 0.47 |
| ▸ | BCHE | P06276 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7607921 | 0.90 | APOB (0.55) | APOBMAPTRXFP1LMNASMN1; SMN2 | |
| SCHEMBL7607440 | 0.88 | MTTP (0.57) | APOBLMNAMTTPGAAPPARG | |
| SCHEMBL7612293 | 0.88 | PPARG (0.52) | APOBMAPTRXFP1LMNASMN1; SMN2 | |
| SCHEMBL7612180 | 0.88 | MTTP (0.61) | CHRNB2CHRNA4APOBRXFP1MTTP | |
| SCHEMBL7607395 | 0.87 | RXFP1 (0.51) | APOBRXFP1MTTPGAAPPARG | |
| SCHEMBL7606402 | 0.86 | MTTP (0.57) | CHRNB2CHRNA4APOBRXFP1MTTP | |
| SCHEMBL7609363 | 0.86 | MTTP (0.57) | CHRNB2CHRNA4APOBRXFP1MTTP | |
| SCHEMBL7613600 | 0.85 | MTTP (0.58) | APOBRXFP1LMNAMTTPPPARG | |
| SCHEMBL7609454 | 0.85 | PPARG (0.59) | APOBMTTPPPARG | |
| SCHEMBL7608067 | 0.85 | MTTP (0.54) | APOBMTTPGAAPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020032238-A1 | Biphenylcarboxylic acid amides, the preparation thereof and the use thereof as medicaments | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2002-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020032238-A1 | Biphenylcarboxylic acid amides, the preparation thereof and the use thereof as medicaments | MTTP, CETP, FABP1 | CHRNB2 4877/4885CHRNA4 4860/4885APOB 45/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.